Skip to content

Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography.

Optimizing Tube Voltage Settings and Injection Parameters for the Individual Patient in CT Pulmonary Angiography.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02611115
Acronym
OptIPeCT
Enrollment
235
Registered
2015-11-20
Start date
2015-09-30
Completion date
2016-12-31
Last updated
2017-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Embolism

Keywords

Pulmonary Embolism, Multidetector Computed Tomography, Radiation Dosage, Contrast Media, Individualized Medicine

Brief summary

Computed tomographic pulmonary angiography (CTPA) is considered the gold standard for the diagnosis of pulmonary embolism (PE). PE is a potentially fatal disease in which a thrombus is lodged into a pulmonary artery blocking blood flow and potentially leading to respiratory distress, acute right cardiac failure or death. Therefore early and correct diagnosis is crucial. The diagnostic and clinical value of CTPA has already been firmly substantiated. Unfortunately up to 7.3% of PE scans are still deemed to be non-diagnostic, for example due to insufficient contrast enhancement in the target arteries. Therefore future research should focus on two important aspects of CT imaging. On the one hand optimal enhancement for the individual patient, on the other hand preventing additional risk of CT imaging - namely contrast induced nephropathy (CIN) and radiation risk. Thus the purpose of our study will be to optimize radiation dose settings (e.g. tube voltage, tube current) and CM application for the individual patient in CTPA.

Interventions

None listed

Sponsors

Bayer
CollaboratorINDUSTRY
Maastricht University Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Suspicion of pulmonary embolism

Exclusion criteria

* Severe allergy against Iopromide or any of the ingredients, previous severe CM reaction (according to current ESUR guidelines), renal insufficiency, pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Image qualityone yearEvaluation of subjective and objective image quality based on individualized CTPA protocols

Secondary

MeasureTime frameDescription
Reduction of radiation doseone yearEffect of individualized tube voltage settings on radiation

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 6, 2026